Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oncostatin m as promoter of immunostimulatory activity of human epithelial cells

An immunostimulatory activity, epithelial cell technology, applied in the field of immunology, can solve the problem of not very favorable clinical benefit and limited efficacy

Inactive Publication Date: 2011-09-28
PROYECTO DE BIOMEDICINA CIMA
View PDF13 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, clinical trials have shown that the efficacy of IFN-α in tumor therapy is very limited, making the clinical benefit not very favorable compared to the side effects, so its current use in oncology is very limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oncostatin m as promoter of immunostimulatory activity of human epithelial cells
  • Oncostatin m as promoter of immunostimulatory activity of human epithelial cells
  • Oncostatin m as promoter of immunostimulatory activity of human epithelial cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0114] To analyze the immunostimulatory properties of OSM on target cells, cytokine-treated human hepatoma cells (Hih7 and HepG2) pulsed with peptide antigens were used to stimulate antigen-specific cytotoxic T lymphocytes. Lymphocyte activation was measured by analyzing their production of IFN-γ, a commonly used marker of T lymphocyte triggering. The production of this Th1 cytokine following T cell antigen recognition has traditionally been considered a readout that correlates with the effector properties of lymphocytes for immunotherapeutic strategies in viral infection and cancer (Brosterhus et al., 1999).

[0115] Materials and methods

[0116] RNA extraction and real-time RT-PCR

[0117] Total RNA extraction was performed using Nucleic Acid Purification Lysate (Applied Biosystems) and the semi-automated system ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems). Real-time RT-PCR was performed as described (Larrea et al., 2006) using specific primers for each ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention refers to the use of oncostatin M (OSM), an OSM receptor (OSMR) agonist, or a combination of OSM or of an OSMR agonist with an interferon of type I (IFN type I), in the manufacture of a medicament to increase the immunostimulatory activity of epithelial cells in a human.

Description

field of invention [0001] The technical field of the invention is immunology. Background of the invention [0002] Oncostatin M (OSM) is a glycoprotein with a molecular weight of approximately 28,000, which is mainly produced by T cells, monocytes / macrophages (Malik, 1989) and dendritic cells (Suda et al., 2002) A pleiotropic cytokine of the IL-6 type (IL-6 is an abbreviation for interleukin-6). It was originally isolated from human leukemia cells and characterized by its ability to inhibit the growth of melanoma cells in vitro (Zarling et al., 1986; Brown et al., 1987). OSM promotes the production of IL-6, an important regulator of the host defense system (Brown et al., 1991), as well as the expression of acute phase proteins (Heinrich, 1998). OSM is currently recognized as a multifunctional cytokine involved in the activation, proliferation and differentiation of several cell types such as hepatocytes, osteoblasts or lung epithelial cells (Grant et al., 1999; Tanaka et a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39C12N5/0783A61K35/14A61K38/19A61K39/00
CPCA61K2039/57A61K2039/55522A61K38/215A61K38/21A61K38/212A61K2039/5158A61K38/204A61K39/39A61K38/19A61P31/04A61P31/10A61P33/00A61P35/00A61P37/04A61K2300/00
Inventor 拉斐尔·阿尔达比阿里奎伊兰祖·宫扎莱兹德拉塔贾德玛利亚·埃丝特·拉瑞莱欧兹赫苏斯·玛利亚·普列托巴尔图埃纳帕布鲁·萨罗韦乌加里萨
Owner PROYECTO DE BIOMEDICINA CIMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com